ElectroCore Aims To Bring Neurostimulation To The Masses, Beginning With Headache

Armed with financing from a syndicate including Merck’s Global Health Innovation Fund, electroCore is pressing ahead with pivotal trials in several headache indications, with other neural and immune conditions to follow. The company believes its noninvasive vagus nerve stimulator that is self-administered by the patient could potentially upturn treatment paradigms.

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Regulation

More from Policy & Regulation